Katarzyna Jowik

Dr. Katarzyna Jowik

Department of Child and Adolescent Psychiatry Poznań

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MTMarta Tyszkiewicz-Nwafor
Marta Tyszkiewicz-Nwafor
KJKatarzyna Jowik
Katarzyna Jowik
ADAgata Dutkiewicz
Agata Dutkiewicz
AKAgata Krasińska
Agata Krasińska
NPNatalia Pytlinska
Natalia Pytlinska
ASAgnieszka Slopien
Agnieszka Slopien
Neuropeptide Y (NPY) and peptide YY (PYY) are involved in metabolic regulation. The purpose of the study was to assess the serum levels of NPY and PYY in adolescents with anorexia nervosa (AN) or obesity (OB), as well as in a healthy control group (CG). The effects of potential confounders on their concentrations were also analysed. Eighty-nine adolescents were included in this study (AN = 30, OB = 30, and CG = 29). Anthropometric measurements and psychometric assessment of depressive symptoms, eating behaviours, body attitudes, and fasting serum levels of NPY and PYY were analysed. The AN group presented severe depressive symptoms, while the OB group held different attitudes towards the body. The levels of NPY were lower in the AN and OB groups as compared with the CG. The PYY levels were higher in the OB group than in the AN group and the CG. The severity of eating disorder symptoms predicted fasting serum concentrations of NPY. Lower levels of NPY in AN, as well as in OB suggests the need to look for a common link in the mechanism of this effect. Higher level of PYY in OB may be important in explaining complex etiopathogenesis of the disease. The psychopathological symptoms may have an influence on the neurohormones regulating metabolism.

1 February 2022 in Neuropeptides
Verified
Journal Article
Closed access
MTMarta Tyszkiewicz-Nwafor
Marta Tyszkiewicz-Nwafor
KJKatarzyna Jowik
Katarzyna Jowik
Elzbieta PaszynskaElzbieta Paszynska
Elzbieta Paszynska
ADAgata Dutkiewicz
Agata Dutkiewicz
ASAgnieszka Słopien
Agnieszka Słopien
MDMonika Dmitrzak-Węglarz
Monika Dmitrzak-Węglarz

12 October 2023 in Neuropeptides
Verified
Journal Article
Open access
MMMagda Katarzyna Malewska-Kasprzak
Magda Katarzyna Malewska-Kasprzak
KJKatarzyna Jowik
Katarzyna Jowik
MTMarta Tyszkiewicz-Nwafor
Marta Tyszkiewicz-Nwafor
Oxytocin (OXT) is a hypothalamic peptide that plays a number of roles in the body, being involved in labor and lactation, as well as cognitive-emotional processes and social behavior. In recent years, knowledge of the physiology of OXT has been repeatedly used to explore its potential role in the treatment of numerous diseases, identifying a significant role for OXT in appetite regulation, eating behavior, weight regulation, and food-related beliefs. In this review we provide an overview of publications on this topic, but due to the wealth of research, we have limited our focus to studies based on the use of intranasal OXT in psychiatric diseases, with a particular focus on the role of oxytocin in eating disorders and obesity. Accumulating evidence that OXT intranasal supplementation may provide some therapeutic benefit seems promising. In individuals with autistic spectrum disorders (ASD) and schizophrenia, OXT may affect core deficits, improving social cognition and reducing symptom severity in schizophrenia. Dysregulation of serum and CSF OXT levels, as well as polymorphisms of its genes, may affect emotion perception in patients with eating disorders and correlate with co-occurring depressive and anxiety disorders. Nevertheless, there are still many critical questions regarding the pharmacokinetics and pharmacodynamics of intranasal OXT that can only be answered in larger randomized controlled trials.

26 September 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
MTMarta Tyszkiewicz-Nwafor
Marta Tyszkiewicz-Nwafor
KJKatarzyna Jowik
Katarzyna Jowik
Background/Objectives: Avoidant/restrictive food intake disorder (ARFID) involves restrictive or avoidant eating causing clinically significant nutritional, medical, developmental, or psychosocial consequences without being primarily driven by weight- or shape-related psychopathology. This review synthesizes evidence on diagnosis, risk assessment, and treatment of ARFID in children and adolescents aged 0–18 years. Methods: We conducted a clinically oriented narrative review informed by a targeted search of English-language publications (1 January 2015–30 June 2026) in PubMed/MEDLINE, Embase, and the Cochrane Library. Results: Nutritional deficiencies, growth faltering, pubertal disruption, and psychosocial impairment may occur across the weight spectrum. ARFID presents through overlapping patterns of limited interest in eating, sensory-based avoidance, and fear of aversive consequences. Assessment should integrate maintaining mechanisms, consequences, and alternative diagnoses. Nutritional rehabilitation and psychological intervention form the foundation of care, although controlled evidence remains limited. One randomized trial reported greater weight gain with family-based treatment than with individual psychoeducational motivational therapy in underweight children, without an overall between-group difference in ARFID symptom severity. Pharmacotherapy has no established efficacy and remains adjunctive. Conclusions: ARFID requires developmentally informed, multidisciplinary assessment and individualized treatment informed by clinical formulation. Prospective comparative studies are needed to clarify long-term outcomes and treatment selection.